ACRS Stock Analysis: Buy, Sell, or Hold?
ACRS - Aclaris Therapeutics, Inc.
$6.41
0.08 (1.26%)
▲
5d:
+10.9%
30d:
+16.97%
90d:
+41.19%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When ACRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ACRS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ACRS shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ACRS is currently trading at $6.41, which is considered extended relative to its 30-day fair value range of $5.36 to $6.11.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is approaching resistance at $6.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACRS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.20 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACRS is in a strong uptrend. The price is approaching resistance at $6.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACRS scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.20 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.36 -
$6.11
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.1% below Wall St target ($10.20)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.36 -
$6.11
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.64
Resistance Level
$6.50
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.89
Wall Street Target
$10.20
(+59.1%)
Revenue Growth (YoY)
-8.3%
Share & Embed Analysis
Last updated: August 23, 2026 7:11 AM ET
Data refreshes hourly during market hours. Next update: 8:11 AM
Data refreshes hourly during market hours. Next update: 8:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$101 | 50 HOLD |
|
SMMT
Summit Therapeutics PLC |
STRONG BUY
10 analysts |
$29 | 55 HOLD |
